Drug intelligence / Profile preview

Erycev

Development stage: Preclinical
Lead developer: PHAXIAM Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Erycev is a proprietary drug delivery technology platform developed by ERYTECH Pharma (now Phaxiam Therapeutics) that utilizes extracellular vesicles derived from red blood cells (RBCs). These RBC-derived vesicles serve as carriers for various therapeutic payloads, including bacteriophages, endolysins, and oncology drugs. The platform is designed to leverage the natural biocompatibility and long circulation half-life of red blood cell components to enhance the delivery, stability, and safety of therapeutic agents. Erycev is being explored for applications in treating antimicrobial-resistant (AMR) infections and in oncology, where it aims to overcome delivery challenges associated with complex biologics by providing protection from immune clearance and facilitating targeted transport.

Brand names: Erycev

Beyond the preview

Go deeper on Erycev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erycev.

Explore the full profile